Swiss National Bank
BOLT icon

Swiss National Bank’s Bolt Biotherapeutics BOLT Stock Holding History

Swiss National Bank’s Portfolio BOLT Stock Details BOLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,400
Closed -$77K – 2750
2022
Q1 		$77K Hold
1,400
– – ﹤0.01% 2691
2021
Q4 		$137K Hold
1,400
– – ﹤0.01% 2719
2021
Q3 		$354K Hold
1,400
– – ﹤0.01% 2610
2021
Q2 		$433K Buy
+1,400
New +$568K ﹤0.01% 2632

Other funds holding BOLT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Swiss National Bank's BOLT Position: Q2 2022 in Review

Swiss National Bank sold out of Bolt Biotherapeutics (BOLT) in Q2 2022, closing a stake of 1,400 shares — an estimated $77K sold.

Swiss National Bank first reported a position in BOLT in Q2 2021 and held it in 4 quarters. The position peaked at $433K in Q2 2021. 61 funds tracked by Wall St. Rank hold BOLT as of Q2 2022.

  • Swiss National Bank reported no remaining Bolt Biotherapeutics position as of Q2 2022 after selling out during the quarter.
  • Swiss National Bank sold 1,400 Bolt Biotherapeutics shares in Q2 2022, an estimated $77K.
  • Swiss National Bank first reported a position in Bolt Biotherapeutics in Q2 2021 and held it in 4 quarters.
  • Swiss National Bank's Bolt Biotherapeutics position peaked at $433K in Q2 2021.
  • 61 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q2 2022.

Based on Swiss National Bank's 13F filing for Q2 2022, filed 9 Aug 2022.